Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

[News]

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

More... (http://www.news-medical.net/news/20100329/Erbitux-can-now-be-used-in-Japan-as-1st-line-treatment-for-mCRC-Merck-Serono.aspx)